Fiera Capital Corp Grows Position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

Fiera Capital Corp boosted its holdings in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 3.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 805,150 shares of the company's stock after purchasing an additional 25,186 shares during the quarter. Fiera Capital Corp owned approximately 1.61% of Immunocore worth $23,889,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in shares of Immunocore during the fourth quarter valued at approximately $25,000. Oppenheimer Asset Management Inc. acquired a new position in shares of Immunocore during the first quarter valued at approximately $225,000. NEOS Investment Management LLC increased its holdings in shares of Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after purchasing an additional 1,102 shares during the last quarter. Tema Etfs LLC acquired a new stake in shares of Immunocore in the fourth quarter valued at approximately $330,000. Finally, Virtus ETF Advisers LLC increased its holdings in shares of Immunocore by 39.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock valued at $340,000 after purchasing an additional 3,238 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on IMCR shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $71.00 price target on shares of Immunocore in a report on Thursday, April 10th. Mizuho cut their price target on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a report on Monday, April 7th. Oppenheimer increased their price target on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. JPMorgan Chase & Co. cut their target price on Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, April 14th. Finally, Wall Street Zen raised Immunocore from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $58.89.

Immunocore Stock Up 0.7%

IMCR traded up $0.22 on Friday, hitting $32.99. 386,223 shares of the company were exchanged, compared to its average volume of 246,217. Immunocore Holdings PLC Sponsored ADR has a twelve month low of $23.15 and a twelve month high of $39.41. The company has a market cap of $1.66 billion, a price-to-earnings ratio of -76.72 and a beta of 0.77. The company has a current ratio of 6.36, a quick ratio of 6.31 and a debt-to-equity ratio of 1.03. The firm has a 50-day moving average price of $34.26 and a two-hundred day moving average price of $31.14.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.45. Immunocore had a negative return on equity of 5.86% and a negative net margin of 6.48%. The firm had revenue of $125.13 million during the quarter, compared to analysts' expectations of $108.82 million. During the same period in the previous year, the firm posted ($0.49) EPS. Immunocore's revenue for the quarter was up 33.6% on a year-over-year basis. On average, equities analysts predict that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.